THANKTIVA
LIVE

Serial Number

97877313

Owner

IMMUNITYBIO, INC.

Attorney

Alicia M. Passerin

First Use Date

Apr 23, 2024

Filing Date

Apr 7, 2023

Add to watchlist:

No watchlists yet
View on USPTO

THANKTIVA Trademark

Serial Number: 97877313

THANKTIVA is a trademark filed by IMMUNITYBIO, INC. on April 7, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

IMMUNITYBIO, INC. (142 trademarks)

3530 JOHN HOPKINS COURT
SAN DIEGO, CA 92121

Entity Type: 03

Trademark Details

Filing Date

April 7, 2023

Registration Date

Not Registered

First Use Anywhere

April 23, 2024

First Use in Commerce

April 23, 2024

Published for Opposition

December 12, 2023

Goods & Services

Pharmaceutical preparations and substances for the treatment of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical preparations and substances for the prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; biological preparations for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases and infectious diseases in the fields of immunotherapy and immuno-oncology; anti-infectives for medical use for the treatment and prevention of immunologic dysfunction, autoimmune diseases and infectious diseases

Medical services; medical information; providing a website featuring medical information in the fields of pharmaceuticals, immunotherapy, immuno-oncology, cancer, autoimmune diseases, and infectious diseases; providing medical information relating to pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases

Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, immunotherapy, immuno-oncology, and the treatment and prevention of cancer, autoimmune diseases, and infectious diseases

Filing History

TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 2, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 1, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 1, 2024 GNRT
SU - NON-FINAL ACTION - WRITTEN
Oct 1, 2024 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Sep 19, 2024 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 19, 2024 AITU
USE AMENDMENT FILED
Jul 17, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Jul 17, 2024 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 17, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jul 17, 2024 EX1G
SOU EXTENSION 1 FILED
Jul 17, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 17, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 6, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 12, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 12, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 7, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 7, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 7, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 7, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 7, 2023 CNEA
ASSIGNED TO EXAMINER
Nov 1, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 2, 2023 NWOS
NEW APPLICATION ENTERED
Apr 11, 2023 NWAP